Organic arsenic compounds

Details Organic arsenic compounds Organic arsenic compounds

2000-11-27

2002-11-19

Rao, Deepak R. (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S186000, C544S226000

Reexamination Certificate

active

06482816

ABSTRACT:

FIELD OF THE INVENTION
This invention relates to novel organic arsenic compounds for treating tumor cells and which are particularly effective for inducing apoptosis in leukemia and breast tumor cells.
BACKGROUND OF THE INVENTION
Cancer is a major disease that continues as one of the leading causes of death at any age. In the United States alone, it is anticipated that more than a half a million Americans will die of cancer in 1999. Currently, radiotherapy and chemotherapy are two important methods used in the treatment of cancer.
Considerable efforts are underway to develop new chemotherapeutic agents for more potent and specific anti-cancer therapy, presenting effective and efficient cytotoxicity against tumor cells, with minimal interference with normal cell function. Accordingly, there is an urgent need for the development and analysis of novel, effective anti-cancer agents.
SUMMARY OF THE INVENTION
New organic arsenic acid substituted cytotoxic agents with potent anti-tumor activity against cancer cells have been synthesized and examined for their effect on human leukemic cells and breast cancer cells. The compounds were found to exhibit potent cytotoxic activity, particularly against human breast cancer and leukemic cell lines, including primary leukemia cells, at micromolar concentrations.
Accordingly, the present invention includes novel compounds and compositions having potent cytotoxic activity. The present invention also includes methods for treating tumors by administering to a subject an anti-tumor effective amount of a compound of the invention. Compositions of the invention contain an effective or inhibitory amount of a organic arsenic acid substituted compound. The compounds of the invention include those having the following formula:
where R is
R
1
is selected from a group consisting of H, NR
3
R
4
, SR
3
and OR
3
, in which R
3
and R
4
are each independently hydrogen or a C
1
-C
4
alkyl group. X is N or C. R
2
is selected from the group consisting of H, NR
3
R
4
, SR
3
, OR
3
, and a group capable of bonding with X, when X is C, to form a fused aromatic or 5- or 6-membered heteroaromatic ring, or a pharmaceutically acceptable salt thereof.


REFERENCES:
patent: 5281588 (1994-01-01), Maes et al.
patent: 6191123 (2001-02-01), Uckun et al.
patent: 997461 (1982-11-01), None
patent: WO 96/16664 (1996-06-01), None
Simone, Oncology: Introduction, Cecil Textbook of Medicine, 20th Edition, vol. 1, pp. 1004-1010, 1996.*
Weinstein SM., “Integrating Palliative Care in Oncology”,Cancer Control,vol. 8 No. 1 pp. 32-35 (Jan./Feb. 2001).
Greenlee RT et al., “Cancer Statistics 2000”,CA-Cancer J. Clin.vol. 50 No. 1 pp. 7-33 (Jan./Feb. 2000).
“Mortality Patterns-United States, 1997”MMWR Morb. Mortal. Wkly. Rep., vol. 48 No. 30 pp. 664-668 (Aug. 6, 1999).
Green JA et al., “Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis”,Lancet, vol. 358 No. 9284 pp. 781-786 (Sep. 8, 2001).
Recht A., “Postmastectomy Locoregional Radiotherapy: Is It Here to Stay?”,Semin Oncol.vol. 28 No. 3 pp. 245-252 (Jun. 2001).
Calvo AR et al., “Lung Cancer: Therapeutic options for stage IV and recurrent NSCLC”,Cancer Treat. Res.vol. 105 pp. 189-227 (2001).
Chen GQ et al., “In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3)in the treatment of acute promyelocytic leukemia: As2O3induces NB4cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR &agr;/PML proteins”,Blood, vol. 88 No. 3 pp. 1052-1061 (Aug. 1, 1996).
Shen ZX et al., “Use of arsenic trioxide (As2O3)in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients”,Blood, vol. 89 No. 9 pp. 3354-3360 (May 1, 1997).
Soignet SL et al., “Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide”,N Engl J Med, vol. 399 No. 19 pp. 1431-1348 (Nov. 5, 1998).
Jing Y et al., “Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway”,Blood, vol. 94 No. 6 pp. 2102-2111 (Sep. 15, 1999).
Zhu XH et al., “Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clincally achievable concentrations”,J Natl Cancer Inst, vol. 91 No. 9 pp. 772-778 (May 5, 1999).
Dai J et al., “Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide throught modulation of the glutathione redox system”,Blood, vol. 93 No. 1 pp. 268-277 (Jan. 1, 1999).
“Arsenic”,Mineral Tolerance of Domestic Animals, The National Academy of Sciences-National Research Council, Washington D.C., pp. 40-53 (1980).
Nomoto et al., “Studies on Cardiotonic Agents. I. Synthesis of Some Quinazoline Derrivatives”,Chem. Pharm. Bull., vol. 38 No. 6 pp. 1591-1595 (Jun. 1990).
Satoh T, “Reduction of organic compounds with sodium borohydride-transition metal salt systems (1) reduction of organic nitrile, nitro and amide compounds to primary amines”,Tetrahedron Letters, vol. 52 pp. 4555-4558 (Nov. 1969).
Andres, R et al., “The Synthesis of Arsonoanilinopyrimidines”,J. Am. Chem. Soc., vol. 67 pp. 946-947 (Jan./Jun. 1945).
Uckun FM et al, “Biotherapy of B-cell pecursor leukemia by targeting genistein to CD19-associated tyrosine kinses.”Sciencevol. 267 No. 5199 pp. 886-891 (Feb. 10, 1995).
Waurzyniak B, “In vivo toxicity, pharmacokinetics, and antileukemic activity of TXU (anti-CD7)-pokeweed antiviral protein immunotoxin”,Clin Cancer Res, vol. 3 pp. 881-890 (Jun. 1997).
Zhu DM, “Calphostin C triggers calcium-dependent apoptosis in human acute lymphoblastic leukemia cells”,Clin Cancer Res, vol. 4 No. 12 pp. 2967-2975 (Dec. 1998).
D'Cruz OJ, “Apoptosis-inducing oxovanadium(IV) complexes of 1,10-phenanthroline against human ovarian cancer”,Anti-Cancer Drugs, vol. 11 No. 10 pp. 849-858 (Nov. 2000).
Gavrieli Y, “Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation”,J Cell Biol, vol. 119 No. 3 pp. 493-501 (Nov. 1992).
Ainley, A. et al., “Trypanocidal activity of some pyrimidylaminophenylarsonic compounds”,Chemical Abstracts, vol. 53, No. 11, pp. 10243-10245 (Jun. 10, 1959).
Gill, B.S., “Chemotherapeutic Susceptibility of Trypanosoma evansi to some arsenicals and suramin-tryparsamid complex”,Acta Vet., vol. 40, No. 2, Abstract only—1 pg. (1971).
Takatsuka, Y. et al., “Various analogs of anthranilic acid and their anti-cancer effects”,Mie Med. J., vol. 17, No. 1, Abstract only-1 pg. (1967).
Yuki, H. et al., “Synthesis of Purine and Pyrimidine Derivatives of Arsonic Acid”,Chem. Pharm. Bull., vol. 15, No. 7, pp. 1052-1055 (1967).

Affiliated with

Also associated with

Rating

Organic arsenic compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Organic arsenic compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Organic arsenic compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2973125